On October 5, 2022 AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") reported an update on the Company’s share repurchase program (the "Share Repurchase Program") authorized by the Company’s Board of Directors on January 21, 2022 (Press release, AIkido Pharma, OCT 5, 2022, View Source [SID1234621750]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share. Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is outstanding."

Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b -18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, including blackout period restrictions.

On October 5, 2022 Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immune-oncology company, reported that an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2022 (Press release, Lytix Biopharma, OCT 5, 2022, View Source [SID1234621749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract will be released on the SITC (Free SITC Whitepaper) website 7 November 14:00 CEST. The poster is scheduled for presentation during the SITC (Free SITC Whitepaper) meeting 8-12th November 2022.

Poster Details:

Abstract Title: Molecular mechanisms of DC activation by melanoma cells responding to LTX-315.

Presenter: Takahiro Yamazaki, Department of Radiation Oncology, Weill Cornell Medical College, New York, USA

About SITC (Free SITC Whitepaper)

The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.

As the largest conference solely focused on cancer immunotherapy, the Annual meeting provides international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.

On October 5, 2022 Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) reported that filing of a provisional patent application with the USPTO entitled "Enhancement of T Cell Homing to Tumors Through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion" with the United States Patent and Trademark Office (Press release, Regen BioPharma, OCT 5, 2022, View Source [SID1234621748]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent application discloses novel means of generating CAR-T cells which upon activation stimulate production of various T cell-specific compounds, called "chemokines" which act as molecular beacons that call in all surrounding T cells and instruct them to kill the cancer cell.

According to an industry report, "Overall, the global CAR-T cell market for all indications was worth $1.7 billion in 2021 and is forecast to reach $2.4 billion by the end of 2022. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. This makes CAR-T cells one of the fastest growing and potentially profitable therapeutic areas in oncology[1]."

"Despite the significant market size of CAR-T cells, this approach has only shown benefit in so called "liquid tumors", which as leukemias and lymphomas. Overall, for reasons known and unknown, solid tumors such as breast, lung, colon, skin and kidney cancer have not benefited" Said David Koos, President, CEO and Chairman. "Our scientific advisors and collaborators tell us that one of the shortcomings of current treatments is that they rely exclusively on the engineered CAR-T cells, which usually are inactivated by the tumor. In the current patent filed we overcome this by using the initial CAR-T cells to stimulate a chain reaction that culminates in education of the patient’s immune response to kill the tumor."

The Company previously has obtained issued US patent #11,090,332 (which covers means of generating T cell immune responses to the solid tumor antigen survivin) as well as US Patent # 11,141,471 covering NR2F6 silenced CAR-T. By combining these technologies with the ones disclosed in the abovementioned patent application filing the Company anticipates development of novel and potentially effective CAR-T cells capable of killing solid tumors, which would significantly expand the market of this new therapy.

On October 5, 2022 LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, reported it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022 (Press release, LadRx, OCT 5, 2022, View Source [SID1234621747]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Executive Officer Stephen Snowdy, PhD commented, "Following up on other changes we have made this year, including the change of our name to LadRx Corporation, we are updating our ticker symbol to better reflect our Company’s focus and brand. Our new name and ticker highlight our unique product platform that has given rise to one clinical drug, Aldoxorubicin, and four pre-clinical therapeutics targeted against cancer, LADRs 7, 8, 9, and 10."

There is no action required by the Company’s current shareholders and the change in its ticker symbol will have no effect on its corporate structure or business. LadRx’s common stock will continue to be listed on the OTCQB, and the CUSIP will remain unchanged.

On October 5, 2022 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies reported four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA (Press release, Adicet Bio, OCT 5, 2022, View Source [SID1234621746]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentations:

Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of γδ T Cell Immunotherapy
Poster/Abstract Number: 198
Presenting Author: Marissa Herrman, Ph.D.
Date/Time: November 11, 2022 from 9:00am – 9:00pm EST

Title: Preclinical Discovery and Characterization of Allogeneic anti-PSMA γδ CAR T Therapy for Prostate Cancer
Poster/Abstract Number: 203
Presenting Author: Nitya S. Ramadoss, Ph.D.
Date/Time: November 10, 2022 from 9:00am – 9:00pm EST

Abstract Title: Allogeneic "off-the-shelf" γδ T cells modified with CD27- containing CAR for targeting CD70+ cancers
Poster/Abstract Number: 246
Presenting Author: Kevin P. Nishimoto, Ph.D.
Date/Time: November 11, 2022 from 9:00am – 9:00pm EST

Abstract Title: Preclinical Discovery and Evaluation of Allogeneic "off-the-shelf" γδ CAR T Cells Targeting B7-H6+ Tumors
Poster/Abstract Number: 247
Presenting Author: Kevin P. Nishimoto, Ph.D.
Date/Time: November 10, 2022 from 9:00am – 9:00pm EST

The abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Monday, November 7 at 8:00am EST on www.sitcancer.org.

R&D Webcast

Adicet will host an R&D webcast presentation on Thursday, November 10, 2022 at 9:00am EST to provide an overview of its R&D pipeline.